Key result
Rosiglitazone treatment was associated with a significant increase in the risk of myocardial infarction in a recent meta-analysis, though primary time-to-event data were absent.
Why the study?
Does rosiglitazone increase the risk of myocardial infarction and cardiovascular death?
Does rosiglitazone increase the risk of myocardial infarction and cardiovascular death?
Answers are grounded in this paper and cite their sources.
This editorial highlights the uncertainty and clinical quandary created by a meta-analysis suggesting increased cardiovascular risk with rosiglitazone.
The recently published meta-analysis by Nissen and Wolski,1 which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an increase of similar magnitude, albeit nonsignificant, in the risk of death from cardiovascular causes, has created a furor in the press and a quandary for physicians and their patients. Given the vagaries of meta-analyses in general and of this meta-analysis in particular — owing to the absence of primary or time-to-event data, as acknowledged both in the article and in the accompanying editorial2 — clinicians have been left uncertain as to whether rosiglitazone . . .
No takes yet. Share an insight, caveat, or question.
David M. Nathan (2007) reported an editorial. Rosiglitazone was evaluated on Myocardial infarction and death from cardiovascular causes. Rosiglitazone treatment was associated with a significant increase in the risk of myocardial infarction in a recent meta-analysis, though primary time-to-event data were absent.
Synapse has enriched 10 related papers. Consider them for comparative context: